AKAbdul Rehman Shahid Khan

Abdul Rehman Shahid Khan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdul Rehman Shahid Khan has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Overlap of Primary Biliary Cholangitis and Systemic Sclerosis: A Case of Reynolds Syndrome

    by Ali Gohar, Ira Abid, Syeda Eman Fatima, Abdum Muneeb Sandhu, Zain Fatima, Humayun Nasir, Fatima Arshad, Abdul Rehman Shahid Khan, Muhammad Husnain Ahmad, Masab Ali

    Reynolds Syndrome should be suspected in CREST patients with persistent cholestatic liver enzymes, since delayed diagnosis allows portal hypertension and variceal bleeding to develop. Early anti‐mitochondrial antibody screening and prompt ursodeoxycholic acid therapy improve outcomes, and these patients need multidisciplinary follow‐up for lung and thyroid disease.

  • Open Access

    May–Thurner Syndrome: An Under‐Recognized Etiology of Deep Vein Thrombosis (DVT)

    by Abdul Rehman Shahid Khan, Yashika Gupta, Betsy Samuel, Yeshwini Murali Krishna, Muhammad Husnain Ahmad, Haseeb Ahmad, Iqra Nasir, Masab Ali, Danish Ali Chohan, Muhammad Umar Nadeem, et al.

    Background and Aims: May–Thurner Syndrome (MTS) is a rare vascular condition characterized by the compression of the left iliac vein by the overlying right iliac artery. This anatomical anomaly predisposes patients, especially young to middle‐aged women, to deep vein thrombosis (DVT), which when it persists, leads to complications such as pulmonary embolism and chronic venous insufficiency. Despite its clinical significance, there is a lack of standardized guidelines for diagnosis and management. This review aims to summarize current knowledge on the epidemiology, pathophysiology, diagnostic approaches, and therapeutic strategies for MTS while highlighting challenges in establishing a consistent clinical framework. Methods: A comprehensive literature search was conducted using PubMed and Google Scholar, focusing on English‐language studies involving human subjects. Sources included case reports, case series, clinical trials, systematic reviews, and expert consensus guidelines. Additional literature on iliac vein pathophysiology and venous thromboembolism management was reviewed to provide broader clinical context. Reference lists of key publications were manually examined for additional relevant studies. The final literature search was completed on April 5, 2025. Results: Common diagnostic methods for MTS include duplex ultrasound, CT venography, and MR venography, with intravascular ultrasound showing the highest sensitivity (> 98%). Endovascular stenting, often combined with catheter‐directed thrombolysis, provides significant symptom relief and reduces post‐thrombotic syndrome. In contrast, angioplasty alone was linked to higher recurrence rates. Long‐term patency rates following stenting ranged from 79% to 100%. However, the absence of standardized diagnostic and treatment protocols contributes to variability in clinical outcomes. Conclusion: MTS remains an underrecognized cause of DVT, especially among young women. Although advances in diagnostic imaging and minimally invasive interventions have improved management, the lack of evidence‐based guidelines continues to interfere with optimal care. Early diagnosis and individualized treatment plans are crucial, and further research is needed to establish evidence‐based protocols for consistent management of MTS.

  • Open Access

    Non‐Specific Interstitial Pneumonia in Anti‐Jo1 Synthetase Syndrome With Probable Gougerot Syndrome: A Case Report

    by Ali Gohar, Ozaire Mohammad, Ruman Shahzad, Fatima Arshad, Abdul Rehman Shahid Khan, Hamad Qayyum, Joham Ajmal, Muhammad Husnain Ahmad

    Anti‐synthetase syndrome (ASS) is a rare autoimmune disorder of idiopathic inflammatory myopathy spectrum, characterized by the presence of aminoacyl‐tRNA synthetase antibodies, most commonly anti‐Jo‐1. Clinically presents with interstitial lung disease (ILD), myositis, and arthritis, and may be confused with other autoimmune conditions such as polymyositis (PM), dermatomyositis (DM), and Sjögren's syndrome. We present a 41‐year‐old French‐Moroccan woman with progressive dyspnea, dry cough, weight loss, and diffuse myalgia. Extensive autoimmune and laboratory investigations revealed positive anti‐histidyl‐transfer RNA synthetase (anti‐Jo‐1), anti‐Ro52, and anti‐cyclic citrullinated peptide (anti‐CCP) antibodies, with elevated creatine phosphokinase (CPK) and lactate dehydrogenase (LDH). Electromyography (EMG) and magnetic resonance imaging (MRI) supported myositis, while chest computed tomography (CT) showed ground‐glass opacities and reticulations consistent with fibrosing interstitial lung disease (ILD). She was diagnosed with anti‐synthetase syndrome (ASS)‐associated ILD. High‐dose corticosteroids, cyclophosphamide, and later tacrolimus, alongside supportive care, were provided, which resulted in significant pulmonary function improvement (forced vital capacity [FVC] 56%–92%, diffusing capacity for carbon monoxide [DLCO] 32%–70%) with preserved exercise tolerance. Our case report illustrates the importance of considering ASS in patients with unexplained ILD and myositis. Prompt recognition and combined immunosuppressive therapy can achieve substantial functional recovery and prevent long‐term respiratory compromise.

  • Open Access

    Association of Atherogenic Index of Plasma With Prediabetics—A Cross‐Sectional Study

    by Ali Gohar, Muhammad Husnain Ahmad, Azhar Nazir, Humza Tariq, Abdul Rehman Shahid Khan, Hamza Zaheer, Nimra Mahmood, Muhammad Zubair, Samra Zulfiqar, Masab Ali, et al.

    Background: Prediabetes, defined as elevated blood glucose levels below the diabetic threshold, is a worldwide concern. In Pakistan, it is highly prevalent. Preventing the progression of diabetes requires early identification of high‐risk people. The Atherogenic Index of Plasma (AIP) has been proposed as an indicator of insulin resistance and cardiovascular risk. Our study content is to explore the relationship between AIP and metabolic indicators in patients with prediabetes. Methodology: A cross‐sectional study was conducted at a tertiary care hospital after IRB approval. A total of 334 prediabetic individuals aged 18–60 years, with no history of diabetes or use of lipid/glucose‐altering medications, were included. Anthropometric, biochemical, and demographic information was gathered, including fasting glucose, HbA1c (Glycated Haemoglobin), and lipid profiles. Different AIP quartiles were assigned to the participants. ANOVA, Chi‐square, and multivariate regression with confounder adjustment were used in the statistical study. Results: Significant differences were observed across AIP quartiles. Higher AIP was associated with male gender, older age, higher BMI, lower HDL (High Density Lipoprotein), and elevated triglycerides. Fasting glucose and insulin increased with AIP, while HbA1c showed no significant variation. In multivariate analysis, HDL and triglycerides remained the strongest independent predictors of AIP. Conclusion: AIP is significantly linked with worsening metabolic indicators in prediabetics, highlighting its potential as a simple, cost‐effective screening tool. Adding AIP into routine evaluations could help early identification and prevention of diabetes and associated cardiovascular disease.

  • Open Access

    Heyde Syndrome: A Literature Review

    by Yashika Gupta, Abdul Rehman Shahid Khan, Viraj Shetty, Yeshwini Murali Krishna, Ayisha Maqsood, Muhammad Husnain Ahmad, Masab Ali, Betsy Samuel, Ali Gohar, Abdul Waheed, et al.

    Background and Aims: Heyde syndrome, a triad of anemia from gastrointestinal (GI) bleeding, aortic valve stenosis, and acquired von Willebrand syndrome, primarily affects individuals over 65. Management requires a multidisciplinary approach, including medical therapy, endoscopic intervention, and valve replacement. Despite advances, many aspects remain unclear. This review explores the epidemiology, pathophysiology, and management of Heyde syndrome while highlighting areas for future research. Methods: A comprehensive search of PubMed and Google Scholar focused on English‐language human studies, including case reports, clinical trials, reviews, and expert guidelines. Additional literature on Von Willebrand syndrome and GI angiodysplasia was reviewed. The final search was completed on April 5, 2025. Results: Aortic valve replacement improves outcomes and hematologic abnormalities. Transcatheter aortic valve replacement (TAVR) showed lower rates of life‐threatening bleeding, fewer perioperative complications, and reduced transfusions compared to surgical replacement. Guidelines recommend dual antiplatelet therapy (DAPT) for 3–6 months post‐TAVR, with 79%–86% of patients experiencing no recurrence of GI bleeds. Management of intestinal angiodysplasia often shows high recurrence rates due to persistent lesions and vWS‐2A. Surgical valve replacement also improves bleeding control, even with anticoagulation. Aortic valve replacement should be first‐line therapy in severe aortic stenosis with chronic GI bleeding. Conclusion: Heyde syndrome remains a complex and often underrecognized condition in elderly populations. Continued research is critical to deepen understanding and improve patient outcomes, allowing for more personalized and effective care strategies.

  • Open Access

    Preemptive EBV-specific T-cell therapy: an emerging prophylactic approach to PTLD reduction and survival benefit in SOT recipients

    by Abdul Rehman Shahid Khan, Roma Bai

    To the Editor, Approximately 90 percent of the population worldwide is infected with the Epstein-Barr virus (EBV), a double-stranded DNA gamma herpesvirus(1). While it affects a large portion of the population, EBV poses a significant risk to individuals undergoing solid organ transplantation (SOT). In these patients, the use of immunosuppressants weakens the immune response, allowing EBV to target naïve B cells, transforming them into rapidly dividing blasts. This may result in posttransplant lymphoproliferative disorders (PTLD)(2). PTLD, a diverse group of cancers, is the second most common malignancy in SOT recipients and is the leading cause of cancer-related death in this population(3). In SOT recipients, the risk of developing PTLD differs mainly based on the EBV serostatus of the donor and recipient and the immunosuppressive treatment regimen employed. EBV-seronegative transplant recipients face the highest incidence of PTLD, as they are susceptible to primary EBV infection after transplantation. Compared to EBV-seropositive recipients (R plus), the relative risk of PTLD in EBV-seronegative individuals (R Minus) ranges from 2.6 to 9.9(4). Considering the severity of the disorder, a recently emerging approach for preventing EBV-related PTLD that involves the use of donor-derived or third-party EBV-specific cytotoxic T lymphocytes (CTLs) has been implemented. The effectiveness of CTLs has been shown for over a decade, with previous studies reporting a 95 percent success rate in subsiding EBV viremia and a 65%-88% success rate in treating PTLD, even in cases where conventional rituximab treatment failed(5). In one observational study of 21 high-risk SOT recipients who received autologous EBV-specific CTLs, only one patient developed PTLD. Although limited by access and HLA compatibility, which posed a challenge for its wide applicability, it is still emerging as a transformative therapy for the prevention of EBV-related PTLD in SOT recipients. To conclude, this letter aims to emphasize the importance of preemptive T cell therapy, particularly the use of EBV-specific CTLs, as a promising strategy for the prevention of PTLD in SOT patients. This is especially crucial for high-risk individuals, such as EBV-seronegative individuals (R Minus). Given the high incidence of PTLD, preemptive T cell therapy has demonstrated significant potential in reducing EBV viremia and preventing the onset of PTLD. We advocate for the implementation of preemptive T cell therapy in high-risk transplant recipients to reduce the burden of PTLD and enhance long-term clinical outcomes in this vulnerable cohort.

  • Open Access

    Paraquat Poisoning: A Case of Daisley–Barton Syndrome and Hepatorenal Failure

    by Ali Gohar, Muhammad Husnain Ahmad, Asad Ullah Mahmood, Usama Naghman, Abdul Rehman Shahid Khan, Hamza Zaheer, Hamza Hafeez Farooqi, Marium Nadeem Khan, Masab Ali

    Paraquat (PQ) is a highly toxic herbicide that causes severe poisoning. It mainly affects the lungs, liver, and kidneys. When ingested intentionally, it has a high mortality rate due to the absence of an effective antidote. We present a rare case of a 35‐year‐old female with deliberate ingestion of paraquat for a suicide attempt. Initially, she was treated conservatively at a local clinic; however, 2 days post‐ingestion, she presented to the emergency department of a tertiary care hospital with complaints of respiratory distress, dysphagia, and mucocutaneous ulcerations. On laboratory examination, liver and renal function tests were deranged (AST 150 U/L, ALT 250 U/L, creatinine 18 mg/dL), and imaging revealed right‐sided pneumothorax. Intensive supportive management (corticosteroids, antibiotics, N‐acetylcysteine, and hemodialysis) was initiated, but the patient rapidly deteriorated, ultimately requiring mechanical ventilation; unfortunately, she succumbed to multi‐organ failure in the Intensive Care Unit (ICU) within an hour of admission. This case report illustrates the novelty of paraquat poisoning and its characteristic clinical presentation (hepatorenal involvement), with atypical Daisley–Barton syndrome in Pakistan. Increased awareness and timely, precise management are crucial for preventing fatal complications, especially in resource‐limited regions, and for mitigating serious case consequences.

  • Open Access

    “Hughes‐Stovin Syndrome: A Comprehensive Narrative Review”

    by Muhammad Mustafa Imran, Abdul Rehman Shahid Khan, Muhammad Usama Younas, Yashika Gupta, Roma Bai, Ali Gohar, Zohaib Iftikhar, Masab Ali, Muhammad Husnain Ahmad, Maryam Saeed, et al.

    Background and Aims: Hughes‐Stovin Syndrome (HSS) is an extremely rare vasculitic disorder characterized by a combination of pulmonary artery aneurysms and deep venous thrombosis (DVT). Often considered a variant or incomplete form of Behçet's disease (BD), it presents diagnostic and therapeutic challenges due to its overlap with other conditions and the lack of standardized criteria. This narrative review aims to describe the epidemiology, pathophysiology, clinical presentation, diagnostic process, treatment strategies, and clinical outcomes associated with HSS. Methods: A narrative review of the literature was conducted using PubMed and Google Scholar. The search included the terms “HSS” OR “pulmonary artery aneurysm” AND “Behçet's disease.” Relevant literature was selected for inclusion based on thematic relevance and clinical importance. Only English‐language articles focusing on human subjects were included, with an emphasis on case reports, series, reviews, and expert opinions. Literature on Behçet's disease was also reviewed for comparative purposes. The reference lists of key articles were manually searched for additional sources. No publication date restrictions were applied. The final search was completed on April 6, 2025. Results: Fewer than 100 cases of HSS have been published in the English‐language literature to date. It primarily affects young adult males and typically presents with hemoptysis, chest pain, and venous thrombosis. Diagnosis is clinical and radiological, with CTPA being the preferred imaging modality. Immunosuppressive therapy remains the cornerstone of management, though there is no consensus on treatment protocols. The use of anticoagulation is controversial due to the risk of aneurysmal rupture. Conclusions: HSS presents significant diagnostic and therapeutic challenges due to its rarity and clinical overlap with other vasculitides. Bridging the current gaps in clinical knowledge will require global collaboration to establish consistent diagnostic standards, deepen our understanding of its underlying mechanisms, and develop evidence‐based treatment protocols.


  • Open Access

    Recurrent Intracerebral Hemorrhage in a 30‐Year‐Old Male With Factor XIII Deficiency: A Case Report

    by Farah Sadiq, Shayan Nawaz, Ali Gohar, Fatima Saleemi, Abdul Rehman Shahid Khan, Masab Ali, Muhammad Husnain Ahmad, Hanzala Zahid, Iqra Nasir

    Spontaneous, nontraumatic intracerebral hemorrhage (ICH) in young adults with bleeding diathesis, particularly Factor XIII (FXIII) deficiency, is a rare yet life‐threatening condition that affects approximately one‐third of patients. FXIII deficiency typically presents at birth with prolonged umbilical bleeding and can manifest later with recurrent episodes of prolonged bleeding, epistaxis, and bleeding from minor injuries. Diagnosing FXIII deficiency is challenging due to a normal coagulation profile, requiring a detailed clinical history and specialized diagnostic tests for FXIII levels. We report a case of a young male with recurrent spontaneous ICH, frequent epistaxis, and prolonged bleeding from minor trauma. The patient was managed conservatively with fresh frozen plasma (FFP) transfusions and supportive care. Prophylactic FFP infusions were initiated every 2 months to prevent further bleeding episodes, accompanied by regular follow‐up. The patient made a full recovery and is now leading a healthy life without excessive bleeding, demonstrating the importance of early diagnosis and ongoing treatment. This case highlights the need for clinicians to consider FXIII deficiency in patients with unexplained bleeding, particularly when routine coagulation tests are normal, and underscores the value of timely intervention to prevent severe complications like ICH.